Compare DexCom, Inc. (DXCM) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Palantir Technologies Inc — how do they compare? DexCom, Inc. trades at $77.8 (market cap $28.06B), while Palantir Technologies Inc trades at $129.41 (market cap $320.66B). The key difference: Palantir Technologies Inc is far larger — about 11.4× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Palantir Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | PLTR | |
|---|---|---|
Market Cap | $28.06B | $320.66B |
Sector | Health | Technology |
52-Week High | $89.53 | $207.18 |
52-Week Low | $54.84 | $107.27 |
Enterprise Value | $27.03B | $312.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Palantir (PLTR) trades at $133.72, up 2.82% today, with strong technical momentum as the stock approaches resistance near $136. The company demonstrates exceptional fundamental performance with 2025 revenue reaching $4.48B and net income soaring to $1.63B, representing a 36.3% profit margin. Recent earnings beats and strategic AI partnerships with companies like Nvidia highlight continued growth potential despite premium valuations.
Outlook remains positive with analyst consensus target of $185.75 suggesting 39% upside potential. Key risks include elevated valuation multiples (P/E 150, P/S 66) and competitive pressures in the AI software space. The upcoming Q2 2026 earnings report on August 3 will be critical for validating current growth trajectory and sustaining investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
